醛固酮靶向治疗:在难治性高血压与慢性肾脏病中的早期实施
难治性高血压常合并慢性肾脏病,两者共存增加心血管不良结局风险,与醛固酮及盐皮质激素受体表达增强相关。盐皮质激素受体拮抗剂被推荐用于难治性高血压,但高钾血症风险限制其在慢性肾脏病患者中的使用。本文综述醛固酮靶向治疗在难治性高血压与慢性肾脏病中的证据与潜在获益,并重新思考临床实践与试验设计。
要点
- 难治性高血压合并慢性肾脏病时醛固酮及盐皮质激素受体表达增强,促进心肾炎症与纤维化。
- 盐皮质激素受体拮抗剂被推荐用于难治性高血压,但高钾血症风险限制其在慢性肾脏病中的使用。
- 非甾体盐皮质激素受体拮抗剂与SGLT2抑制剂延缓肾功能下降并显示心肾获益。
核心结论
- 醛固酮靶向治疗在难治性高血压合并慢性肾脏病中具有潜在获益,需重新考虑临床实践与试验设计。
- 仅降低血压可能不足以预防心肾疾病进展风险。
研究设计与样本
- 本文为综述,呈现醛固酮靶向治疗在难治性高血压与慢性肾脏病中的证据与潜在获益。
主要发现
- 难治性高血压与慢性肾脏病共存增加不良心血管结局风险。
- 难治性高血压与慢性肾脏病患者醛固酮及盐皮质激素受体表达增强,促进心肾组织炎症与纤维化。
- 盐皮质激素受体拮抗剂的疗效主要在肾功能正常人群中研究。
- 非甾体盐皮质激素受体拮抗剂和SGLT2抑制剂延缓肾功能下降并显示心肾获益。
- 醛固酮合成酶抑制剂可能成为难治性高血压的治疗选择。
关键数值与推荐
- 盐皮质激素受体拮抗剂被推荐用于难治性高血压的治疗。
- 难治性高血压临床试验主要评估降压效果。
临床怎么用
- 难治性高血压合并慢性肾脏病管理需兼顾血压控制与醛固酮相关不良事件风险。
- 慢性肾脏病患者使用盐皮质激素受体拮抗剂需关注高钾血症风险。
- 非甾体盐皮质激素受体拮抗剂和SGLT2抑制剂可考虑用于心肾获益。
局限性
- 盐皮质激素受体拮抗剂的疗效主要在肾功能正常人群中研究。
- 高钾血症风险限制盐皮质激素受体拮抗剂在慢性肾脏病患者中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-resistant hypertension (TRH) often coexists with chronic kidney disease (CKD), and the presence of both conditions increases the risk of adverse cardiovascular outcomes. Patients with TRH and CKD exhibit enhanced aldosterone and mineralocorticoid receptor expression, which promote inflammation and fibrosis in cardiac and renal tissues, contributing to the development and progression of cardiorenal diseases. Both achieving optimal blood pressure (BP) control and mitigating the risk of aldosterone-related adverse events are cornerstones in the management of patients with TRH and CKD. Mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of TRH. To date, the efficacy has been investigated in populations with mostly normal renal function. However, the potential risk of hyperkalaemia limits the use of MRAs, particularly in patients with CKD. Non-steroidal MRAs and sodium glucose cotransporter-2 inhibitors have slowed renal function decline and shown cardiorenal benefits. Additionally, aldosterone synthase inhibitors may emerge as a therapeutic option for patients with TRH. Clinical trials for TRH primarily centred on assessing BP-lowering effects; however, merely lowering BP might not be a sufficient target to prevent a risk of cardiorenal disease progression. This paper presents evidence and potential benefits of aldosterone-targeted therapy in the treatment of TRH and CKD and re-consider the treatment strategies in clinical practice and trial design.
引用
- Kobayashi M, Pitt B, Ferreira JP, et al. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. Eur Heart J. 2025. PMID: 40214750. doi:10.1093/eurheartj/ehaf225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。